The Role of Optical Coherence Tomography in the Evaluation of Ocular Photodynamic Therapy
Clinical studies in vitreoretinal disorders utilize a variety of modalities in order to assess the retina’s response to different therapies. The standard methods include visual acuity assessment, clinical examination, angiography, and electrophysiologic testing. Visual acuity is a primary outcome in most ophthalmology studies. It is measured by standardized techniques such as the Early Treatment for Diabetic Retinopathy Study (ETDRS) chart or the modified Bailey-Lovie chart. Clinical examination may involve a certified study examiner or multiple examiners and it may be performed in a masked fashion. Angiography with fluorescein dye is used to assess the posterior segment circulation. It has traditionally been the gold standard test to diagnose and classify choroidal neovascularization (CNV), as well as to evaluate the response of CNV to therapy. Indocyanine green (ICG) dye, which was originally used in cardiovascular imaging, has recently found applications in ophthalmology. The molecular and fluorescent properties of ICG permit improved imaging of the choroidal circulation. In some cases, ICG may permit evaluation of pathology, which is not visualized with fluorescein angiography due to blockage by hemorrhage. Electrophysiologic tests such as the electroretinogram (ERG) and electro-oculogram (EOG) are useful to localize pathology to a specific level or location in the retina and to monitor the effect of therapy.
KeywordsOptical Coherence Tomography Retinal Pigment Epithelium Photodynamic Therapy Cystoid Macular Edema Optical Coherence Tomography Imaging
Unable to display preview. Download preview PDF.
- 3.Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol 1999;117:1329–1345.Google Scholar
- 5.Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Macular photocoagulation study group. Arch Ophthalmol 1994;112:489–499.Google Scholar
- 6.Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Macular photocoagulation study group. Arch Ophthalmol 1994;112:480–488.Google Scholar
- 7.Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular photocoagulation study group. Arch Ophthalmol 1993;111:1200–1209.Google Scholar
- 15.Rosenfeld PJ, Heier JS, Chung CY, McCluskey ER. RhuFab V2 Dose-escalation trial: safety and tolerability of 3 escalating dosing regimens in subjects with age-related macular degeneration. Abstract. New York: American Society of Retina Specialists, August 2003.Google Scholar
- 16.Antoszyk AN, Sy JP, McCluskey ER, rhuFabV2 Study Group. RhuFab V2 in wet AMD: changes in OCT measures of the ocular edema. Abstract. New York: American Society of Retina Specialist, August 2003.Google Scholar